Predictors of Mortality in Patients With Multiple Endocrine Neoplasia Type 1
Authors' conclusion
Patients with MEN 1 diagnosed before age 45 with adrenal nodularity, hypergastrinaemia or liver lesions had significantly reduced survival. The explanation for non-secretory and benign adrenal macronodular hyperplasia being associated with diminished life expectancy is unclear.
Study context
- Population
- Patients with MEN1 with a common MEN1 genotypecommon MEN1 genotype
- Participants
- 130 patients
- Exposure
- Diagnosis of MEN1 manifestations before vs after age 45 years
- Outcome
- Median life expectancy (MLE), Kaplan-Meier survival analysis
Methodological detailstertiary hospital based
- Tertiary hospital based
Main finding
As reported in the abstract
Predictors of survival (MLE)
- Overall cohort median life expectancy (MLE)
- 70.8 years
- Adrenal nodularity diagnosed <45 years: MLE; reduction in survival vs later diagnosis
- MLE 51.8 years; reduction 26.2 years, p < 0.01
- Hypergastrinaemia diagnosed <45 years: MLE; reduction in survival vs later diagnosis
- MLE 66.2 years; reduction 6.4 years, p = 0.03
- Liver lesions diagnosed <45 years: MLE; reduction in survival vs later diagnosis
- MLE 38.6; reduction 30.3 years, p < 0.01
- Pancreatic nodularity diagnosed <45 years: MLE; not predictive of survival
- MLE 68.9 years
- PHPT diagnosed <45 years: MLE; not predictive of survival
- MLE 68.9 years
Observational data: associations, not effects.
Original publication
Predictors of Mortality in Patients With Multiple Endocrine Neoplasia Type 1. Clin Endocrinol (Oxf). Published 2 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →